These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18430192)

  • 21. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
    Shander A; Spence RK; Auerbach M
    Transfusion; 2010 Mar; 50(3):719-32. PubMed ID: 19919555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patients.
    Steinmetz T; Kuhr K; Totzke U; Hellmich M; Heinz M; Neise M; Mittermüller J; Tessen HW; Reiser M; Severin K; Schmitz S
    Clin Chem Lab Med; 2013 Sep; 51(9):1849-57. PubMed ID: 23729581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
    Shord SS; Hamilton JM; Cuellar S
    J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
    Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
    Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future directions in management of anemia in heart failure.
    Agarwal AK; Katz SD
    Heart Fail Clin; 2010 Jul; 6(3):385-95. PubMed ID: 20630412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.
    Sanz Ortiz J
    Clin Transl Oncol; 2008 Aug; 10(8):486-92. PubMed ID: 18667379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
    Katodritou E; Dimopoulos MA; Zervas K; Terpos E
    Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [How do we need to maintain the iron status in dialyzed patients treated with erythropoesis stimulating agents].
    Kes P; Basić-Jukići N; Jurić I
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():54-61. PubMed ID: 20232552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?
    Dahl NV; Henry DH; Coyne DW
    Semin Dial; 2008; 21(3):210-1. PubMed ID: 18397204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?].
    Kessler M; Salignac S; Aimone-Gastin I
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S261-5. PubMed ID: 17373268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study.
    Spielmann M; Luporsi E; Ray-Coquard I; de Botton S; Azria D; Lasocki S; Lafuma A; Mahi L; Deray G; Bugat R
    Eur J Cancer; 2012 Jan; 48(1):101-7. PubMed ID: 22044579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
    Singh A
    Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials.
    Gafter-Gvili A; Rozen-Zvi B; Vidal L; Leibovici L; Vansteenkiste J; Gafter U; Shpilberg O
    Acta Oncol; 2013 Jan; 52(1):18-29. PubMed ID: 22877242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoietin in cancer patients.
    Glaspy JA
    Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
    Costiniuk CT; Camacho F; Cooper CL
    Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should intravenous iron be the standard of care in oncology?
    Auerbach M
    J Clin Oncol; 2008 Apr; 26(10):1579-81. PubMed ID: 18375888
    [No Abstract]   [Full Text] [Related]  

  • 38. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective observational study of anaemia management in cancer patients - results from the German Cancer Anaemia Registry.
    Steinmetz T; Totzke U; Schweigert M; Mittermüller J; Nawka S; Tesch H; Groschek M; Söling U; Hellebrand E; Tsamaloukas A
    Eur J Cancer Care (Engl); 2011 Jul; 20(4):493-502. PubMed ID: 21029222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: a prospective study.
    Theusinger OM; Leyvraz PF; Schanz U; Seifert B; Spahn DR
    Anesthesiology; 2007 Dec; 107(6):923-7. PubMed ID: 18043060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.